Boston Scientific (NYSE:BSX) Shares Gap Down – What’s Next?

Boston Scientific Corporation (NYSE:BSX)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $49.86, but opened at $47.00. Boston Scientific shares last traded at $47.7710, with a volume of 8,395,832 shares traded.

Analyst Ratings Changes

Several research firms have weighed in on BSX. Jefferies Financial Group dropped their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. Daiwa Securities Group downgraded shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Truist Financial dropped their price objective on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Stock Performance

The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market cap of $69.31 billion, a PE ratio of 19.36, a P/E/G ratio of 1.07 and a beta of 0.56. The stock’s 50 day simple moving average is $46.44 and its two-hundred day simple moving average is $57.14.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger purchased 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 194,522 shares of company stock valued at $9,385,210 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently bought and sold shares of the business. CYBER HORNET ETFs LLC increased its holdings in Boston Scientific by 3.4% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock worth $391,000 after acquiring an additional 132 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management lifted its holdings in Boston Scientific by 4.7% during the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 139 shares during the last quarter. Northwestern Mutual Investment Management Company LLC boosted its position in Boston Scientific by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock worth $4,516,000 after purchasing an additional 140 shares during the period. Kingsview Wealth Management LLC increased its stake in shares of Boston Scientific by 2.4% in the fourth quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock worth $578,000 after purchasing an additional 142 shares in the last quarter. Finally, Uptick Partners LLC lifted its stake in shares of Boston Scientific by 5.6% during the 4th quarter. Uptick Partners LLC now owns 2,699 shares of the medical equipment provider’s stock valued at $257,000 after buying an additional 143 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.